These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 28838379)

  • 1. Phase II study of olaratumab with paclitaxel/carboplatin (P/C) or P/C alone in previously untreated advanced NSCLC.
    Gerber DE; Swanson P; Lopez-Chavez A; Wong L; Dowlati A; Pennell NA; Cronier DM; Qin A; Ilaria R; Cosaert J; Shahir A; Baggstrom MQ
    Lung Cancer; 2017 Sep; 111():108-115. PubMed ID: 28838379
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An Open-Label, Randomized, Controlled Phase II Study of Paclitaxel-Carboplatin Chemotherapy With Necitumumab Versus Paclitaxel-Carboplatin Alone in First-Line Treatment of Patients With Stage IV Squamous Non-Small-Cell Lung Cancer.
    Spigel DR; Luft A; Depenbrock H; Ramlau R; Khalil M; Kim JH; Mayo C; Chao GY; Obasaju C; Natale R
    Clin Lung Cancer; 2017 Sep; 18(5):480-488. PubMed ID: 28365238
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A randomized phase 2 study of paclitaxel and carboplatin with or without conatumumab for first-line treatment of advanced non-small-cell lung cancer.
    Paz-Ares L; Bálint B; de Boer RH; van Meerbeeck JP; Wierzbicki R; De Souza P; Galimi F; Haddad V; Sabin T; Hei YJ; Pan Y; Cottrell S; Hsu CP; RamLau R
    J Thorac Oncol; 2013 Mar; 8(3):329-37. PubMed ID: 23370314
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase II trial of nanoparticle albumin-bound paclitaxel, carboplatin, and bevacizumab in first-line patients with advanced nonsquamous non-small cell lung cancer.
    Reynolds C; Barrera D; Jotte R; Spira AI; Weissman C; Boehm KA; Pritchard S; Asmar L
    J Thorac Oncol; 2009 Dec; 4(12):1537-43. PubMed ID: 19887966
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Randomized phase III placebo-controlled trial of carboplatin and paclitaxel with or without the vascular disrupting agent vadimezan (ASA404) in advanced non-small-cell lung cancer.
    Lara PN; Douillard JY; Nakagawa K; von Pawel J; McKeage MJ; Albert I; Losonczy G; Reck M; Heo DS; Fan X; Fandi A; Scagliotti G
    J Clin Oncol; 2011 Aug; 29(22):2965-71. PubMed ID: 21709202
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A phase 2 study of bevacizumab in combination with carboplatin and paclitaxel in patients with non-squamous non-small-cell lung cancer harboring mutations of epidermal growth factor receptor (EGFR) after failing first-line EGFR-tyrosine kinase inhibitors (HANSHIN Oncology Group 0109).
    Hattori Y; Satouchi M; Shimada T; Urata Y; Yoneda T; Mori M; Nishimura T; Sunadome H; Kumagai T; Imamura F; Fujita S; Kaji R; Hata A; Tachihara M; Morita S; Negoro S
    Lung Cancer; 2015 Feb; 87(2):136-40. PubMed ID: 25553650
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 2.
    Herbst RS; Giaccone G; Schiller JH; Natale RB; Miller V; Manegold C; Scagliotti G; Rosell R; Oliff I; Reeves JA; Wolf MK; Krebs AD; Averbuch SD; Ochs JS; Grous J; Fandi A; Johnson DH
    J Clin Oncol; 2004 Mar; 22(5):785-94. PubMed ID: 14990633
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Randomized phase II study of paclitaxel/carboplatin intercalated with gefitinib compared to paclitaxel/carboplatin alone for chemotherapy-naïve non-small cell lung cancer in a clinically selected population excluding patients with non-smoking adenocarcinoma or mutated EGFR.
    Choi YJ; Lee DH; Choi CM; Lee JS; Lee SJ; Ahn JH; Kim SW
    BMC Cancer; 2015 Oct; 15():763. PubMed ID: 26493267
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Weekly regimen of paclitaxel and carboplatin as first-line chemotherapy in elderly patients with stage IIIB-IV non small cell lung cancer (NSCLC): results of a phase II study.
    Rozzi A; Nardoni C; Corona M; Restuccia MR; Falbo T; Lanzetta G
    J Chemother; 2010 Dec; 22(6):419-23. PubMed ID: 21303751
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Randomized phase II study of carboplatin and paclitaxel with either linifanib or placebo for advanced nonsquamous non-small-cell lung cancer.
    Ramalingam SS; Shtivelband M; Soo RA; Barrios CH; Makhson A; Segalla JG; Pittman KB; Kolman P; Pereira JR; Srkalovic G; Belani CP; Axelrod R; Owonikoko TK; Qin Q; Qian J; McKeegan EM; Devanarayan V; McKee MD; Ricker JL; Carlson DM; Gorbunova VA
    J Clin Oncol; 2015 Feb; 33(5):433-41. PubMed ID: 25559798
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cetuximab and first-line taxane/carboplatin chemotherapy in advanced non-small-cell lung cancer: results of the randomized multicenter phase III trial BMS099.
    Lynch TJ; Patel T; Dreisbach L; McCleod M; Heim WJ; Hermann RC; Paschold E; Iannotti NO; Dakhil S; Gorton S; Pautret V; Weber MR; Woytowitz D
    J Clin Oncol; 2010 Feb; 28(6):911-7. PubMed ID: 20100966
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bavituximab plus paclitaxel and carboplatin for the treatment of advanced non-small-cell lung cancer.
    Digumarti R; Bapsy PP; Suresh AV; Bhattacharyya GS; Dasappa L; Shan JS; Gerber DE
    Lung Cancer; 2014 Nov; 86(2):231-6. PubMed ID: 25236982
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Olaratumab and doxorubicin versus doxorubicin alone for treatment of soft-tissue sarcoma: an open-label phase 1b and randomised phase 2 trial.
    Tap WD; Jones RL; Van Tine BA; Chmielowski B; Elias AD; Adkins D; Agulnik M; Cooney MM; Livingston MB; Pennock G; Hameed MR; Shah GD; Qin A; Shahir A; Cronier DM; Ilaria R; Conti I; Cosaert J; Schwartz GK
    Lancet; 2016 Jul; 388(10043):488-97. PubMed ID: 27291997
    [TBL] [Abstract][Full Text] [Related]  

  • 14. International, randomized, placebo-controlled, double-blind phase III study of motesanib plus carboplatin/paclitaxel in patients with advanced nonsquamous non-small-cell lung cancer: MONET1.
    Scagliotti GV; Vynnychenko I; Park K; Ichinose Y; Kubota K; Blackhall F; Pirker R; Galiulin R; Ciuleanu TE; Sydorenko O; Dediu M; Papai-Szekely Z; Banaclocha NM; McCoy S; Yao B; Hei YJ; Galimi F; Spigel DR
    J Clin Oncol; 2012 Aug; 30(23):2829-36. PubMed ID: 22753922
    [TBL] [Abstract][Full Text] [Related]  

  • 15. BEYOND: A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase III Study of First-Line Carboplatin/Paclitaxel Plus Bevacizumab or Placebo in Chinese Patients With Advanced or Recurrent Nonsquamous Non-Small-Cell Lung Cancer.
    Zhou C; Wu YL; Chen G; Liu X; Zhu Y; Lu S; Feng J; He J; Han B; Wang J; Jiang G; Hu C; Zhang H; Cheng G; Song X; Lu Y; Pan H; Zheng W; Yin AY
    J Clin Oncol; 2015 Jul; 33(19):2197-204. PubMed ID: 26014294
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Phase II study of pulse dose imatinib mesylate and weekly paclitaxel in patients aged 70 and over with advanced non-small cell lung cancer.
    Bauman JE; Eaton KD; Wallace SG; Carr LL; Lee SJ; Jones DV; Arias-Pulido H; Cerilli LA; Martins RG
    BMC Cancer; 2012 Oct; 12():449. PubMed ID: 23033932
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase 1b/2 Randomized Study of MEDI-575 in Combination With Carboplatin Plus Paclitaxel Versus Carboplatin Plus Paclitaxel Alone in Adult Patients With Previously Untreated Advanced Non-Small-Cell Lung Cancer.
    Wheatley-Price P; Gadgeel S; Takahashi T; Li X; Dar M; Blumenschein GR
    Clin Lung Cancer; 2019 May; 20(3):e362-e368. PubMed ID: 30685114
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase II trial of mapatumumab, a fully human agonist monoclonal antibody to tumor necrosis factor-related apoptosis-inducing ligand receptor 1 (TRAIL-R1), in combination with paclitaxel and carboplatin in patients with advanced non-small-cell lung cancer.
    von Pawel J; Harvey JH; Spigel DR; Dediu M; Reck M; Cebotaru CL; Humphreys RC; Gribbin MJ; Fox NL; Camidge DR
    Clin Lung Cancer; 2014 May; 15(3):188-196.e2. PubMed ID: 24560012
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Randomized phase II study of ixabepilone or paclitaxel plus carboplatin in patients with non-small-cell lung cancer prospectively stratified by beta-3 tubulin status.
    Edelman MJ; Schneider CP; Tsai CM; Kim HT; Quoix E; Luft AV; Kaleta R; Mukhopadhyay P; Trifan OC; Whitaker L; Reck M
    J Clin Oncol; 2013 Jun; 31(16):1990-6. PubMed ID: 23589560
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Weekly paclitaxel in combination with carboplatin for advanced non-small-cell lung cancer complicated by idiopathic interstitial pneumonias: a single-arm phase II study.
    Fukuizumi A; Minegishi Y; Omori M; Atsumi K; Takano N; Hisakane K; Takahashi S; Kobayashi K; Sugano T; Takeuchi S; Noro R; Seike M; Kubota K; Azuma A; Gemma A
    Int J Clin Oncol; 2019 Dec; 24(12):1543-1548. PubMed ID: 31352631
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.